Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.27 USD | +2.79% | +2.31% | -11.53% |
05-14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
05-13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.53% | 479M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.99% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-13-2022 09